Free Trial
NASDAQ:TGTX

TG Therapeutics (TGTX) Stock Price, News & Analysis

TG Therapeutics logo
$32.21 +1.30 (+4.21%)
(As of 12:45 PM ET)

About TG Therapeutics Stock (NASDAQ:TGTX)

Key Stats

Today's Range
$29.84
$33.38
50-Day Range
$21.31
$30.91
52-Week Range
$10.42
$33.38
Volume
4.48 million shs
Average Volume
3.67 million shs
Market Capitalization
$5.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.67
Consensus Rating
Moderate Buy

Company Overview

TG Therapeutics Inc is a biopharmaceutical company that develops and commercializes innovative treatments for multiple sclerosis (MS) and other autoimmune diseases. The company, founded in 2012, is headquartered in New York City and has operations in the United States and Europe. The company aims to provide new and effective therapies to patients with unmet medical needs.

TG Therapeutics has made significant achievements since its inception but has also experienced significant setbacks. The company initially rose to fame by producing the cancer drug Ukoniq which was later pulled from the market due to its ineffectiveness. The company shifted focus and received FDA approvals for a multiple sclerosis drug, Briumvi, for relapsing forms of multiple sclerosis. Additionally, the company conducts extensive clinical trials for other product candidates. These product candidates can potentially provide new treatment options for patients with B-cell malignancies and autoimmune diseases.

TG Therapeutics has a talented and experienced management team dedicated to advancing the company's mission. The current CEO and co-founder of the company is Michael S. Weiss, who has over 25 years of experience in the biopharmaceutical industry. TG Therapeutics has seen financial growth and decline over the past few years. The company has reported significant losses primarily due to removing Ukoniq from its product line and increased investment in clinical development and research activities. 

TG Therapeutics has seen significant volatility in its stock price over the past few years. In 2021, the stock price increased by over 200% due to positive clinical trial results for its product candidates. However, in 2022, the stock price experienced a sharp decline due to concerns about removing the approved drug Ukoniq from the market, delays in clinical development and increased competition. 

TG Therapeutics operates in the biopharmaceutical industry, characterized by high innovation levels and significant regulatory oversight. The industry is also subject to political and economic pressures, including changes in healthcare policy and pricing pressures from payers.

TG Therapeutics faces competition from other companies developing cancer and autoimmune disease treatments, including large pharmaceutical companies such as Roche and Novartis. However, the company's focus on developing novel therapies for unmet medical needs gives it a competitive advantage.

TG Therapeutics has several growth opportunities in its pipeline. The company is currently developing new product candidates which have the potential to provide new treatment options for patients with MS, B-cell malignancies and autoimmune diseases. Additionally, the company may pursue strategic acquisitions or partnerships to expand its product portfolio and reach new markets.

TG Therapeutics faces risks and challenges that may impact its future growth and success. These include changes in healthcare policy and pricing pressures from payers and increased competition from other companies in the market. Additionally, the company is subject to regulatory oversight and must successfully navigate the clinical development and approval process for its product candidates. Failure to do so may result in delays, increased costs, and potential setbacks for the company.

The company's financial performance is also subject to risks, such as changes in interest rates and the availability of financing. The company's debt levels may limit its ability to invest in research and development. Any significant changes in ownership or management may also disrupt operations and impact the company's growth potential.

Furthermore, the success of TG Therapeutics' product candidates is not guaranteed, and the company may need help demonstrating their safety and efficacy in clinical trials. Failure to obtain regulatory approval for these products or to effectively commercialize them may significantly impact the company's financial performance and market position.

TG Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
83rd Percentile Overall Score

TGTX MarketRank™: 

TG Therapeutics scored higher than 83% of companies evaluated by MarketBeat, and ranked 207th out of 986 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    TG Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    TG Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about TG Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for TG Therapeutics are expected to grow by 511.76% in the coming year, from $0.17 to $1.04 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of TG Therapeutics is -320.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of TG Therapeutics is -320.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    TG Therapeutics has a P/B Ratio of 26.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about TG Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    23.06% of the float of TG Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    TG Therapeutics has a short interest ratio ("days to cover") of 8.9.
  • Change versus previous month

    Short interest in TG Therapeutics has recently decreased by 1.48%, indicating that investor sentiment is improving.
  • Dividend Yield

    TG Therapeutics does not currently pay a dividend.

  • Dividend Growth

    TG Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    23.06% of the float of TG Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    TG Therapeutics has a short interest ratio ("days to cover") of 8.9.
  • Change versus previous month

    Short interest in TG Therapeutics has recently decreased by 1.48%, indicating that investor sentiment is improving.
  • News Sentiment

    TG Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 36 news articles for TG Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    28 people have searched for TGTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    11 people have added TG Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 175% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, TG Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $152,200.00 in company stock.

  • Percentage Held by Insiders

    10.50% of the stock of TG Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    58.58% of the stock of TG Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about TG Therapeutics' insider trading history.
Receive TGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TGTX Stock News Headlines

New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
FY2024 EPS Estimate for TG Therapeutics Boosted by Analyst
B. Riley Reduces Earnings Estimates for TG Therapeutics
TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $55.00
TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $22.00
See More Headlines

TGTX Stock Analysis - Frequently Asked Questions

TG Therapeutics' stock was trading at $17.08 at the start of the year. Since then, TGTX shares have increased by 87.9% and is now trading at $32.10.
View the best growth stocks for 2024 here
.

TG Therapeutics, Inc. (NASDAQ:TGTX) announced its earnings results on Monday, November, 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by $0.01. The firm's revenue was down 49.4% compared to the same quarter last year.

Top institutional investors of TG Therapeutics include Charles Schwab Investment Management Inc. (0.77%), FMR LLC (0.76%), Principal Financial Group Inc. (0.50%) and Swiss National Bank (0.19%). Insiders that own company stock include Michael S Weiss, Sean A Power, Laurence N Charney, Yann Echelard and Sagar Lonial.
View institutional ownership trends
.

Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that TG Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
11/04/2024
Today
11/13/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/26/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TGTX
Employees
290
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$37.67
High Stock Price Target
$55.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+21.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$12.67 million
Pretax Margin
27.62%

Debt

Sales & Book Value

Annual Sales
$233.66 million
Cash Flow
$0.09 per share
Book Value
$1.06 per share

Miscellaneous

Free Float
138,567,000
Market Cap
$4.79 billion
Optionable
Optionable
Beta
2.19

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:TGTX) was last updated on 11/13/2024 by MarketBeat.com Staff
From Our Partners